Latest Insights - page 19 | BiopharmaTrend

Manas AI Raises $26M Seed Extension and Appoints Ujjwal Singh as CTO and Co-Founder

Manas AI, a New York–based company developing AI-native drug discovery and development technologies, has closed a $26 million seed extension round and named Ujjwal Singh as Co-Founder and Chief Technology …

Continue ›››

Merck Expands Variational AI Collaboration To Up-To-$349M Deal On Two Small-Molecule Targets

Merck converted an earlier evaluation of Variational AI’s Enki platform into a collaboration to generate and optimize small-molecule candidates for two undisclosed, Merck-selected targets. The agreement includes an undisclosed upfront …

Continue ›››

MindWalk Advances AI-Designed GLP-1 Program With Dual-Pathway Regimen for Longevity

MindWalk, formerly known as ImmunoPrecise Antibodies (IPA), has expanded its AI-driven GLP-1 therapeutics program by introducing a dual-pathway regimen aimed at aging and longevity. The approach combines the company’s AI-optimized …

Continue ›››

NetraMark Launches AI-Powered Study of Glioblastoma Clinical Data

Toronto based NetraMark Holdings has entered a collaboration with a U.S. academic medical center to apply its explainable artificial intelligence platform, NetraAI, to glioblastoma datasets. The agreement provides NetraMark with …

Continue ›››

Revvity and Profluent Partner on AI-Engineered Base Editing Toolkit

Revvity has announced a collaboration with Profluent to integrate AI-designed adenine deaminase enzymes into its Pin-point base editing platform. The partnership is intended to expand the precision and flexibility of …

Continue ›››

Infinitus Partners with IBM Consulting to Automate Patient Access with AI Agents

Infinitus, a San Francisco–based company focused on conversational AI for healthcare administration, has partnered with IBM Consulting, the professional services arm of IBM that advises on large-scale technology transformation, to …

Continue ›››

Salt AI Raises $10M for Drag-and-Drop Platform to Build AI Workflows in Life Sciences

Salt AI closed a $10 million round led by Morpheus Ventures, with Struck Capital, Marbruck Investments, and CoreWeave participating. The company plans to expand deployments with biopharma and healthcare customers …

Continue ›››

Trially AI Raises $4.7M Seed Round, Launches AI for Clinical Trial Enrollment

Trially AI has secured $4.7 million in seed financing led by Flyover Capital, with participation from Alpaca, Atria, Blu Ventures, Looking Glass Capital, Redbud, The Council, and Gaingels. The company …

Continue ›››

Helmholtz Munich and Parse Biosciences Partner to Build Largest Human Lung Tissue Perturbation Atlas

Helmholtz Munich and Parse Biosciences have launched a collaboration to generate an atlas of human lung tissue perturbations. The project uses Parse’s GigaLab single-cell sequencing platform to examine how healthy …

Continue ›››

Immuto Raises $8M Seed for AI Structural Surfaceomics, Enters Daiichi Sankyo Oncology Collaboration

Immuto Scientific has closed an oversubscribed $8 million Seed 2 financing round led by DYDX, with participation from WARF Ventures, Gravity Fund, and Great Oaks Venture Capital, among others, and …

Continue ›››

T.Rx Capital Raises $77.5M to Back Early-Stage Biotech and Digital Health

T.Rx Capital closed a $77.5 million inaugural fund to back early-stage companies at the interface of technology and biology, targeting biotechnology "techbio" and tech-enabled services. The firm plans a concentrated …

Continue ›››

Enveda Starts Phase 1b of AI-Discovered Small-Molecule Anti-Inflammatory for Atopic Dermatitis

Dr. Vince Clinical Research, based in Overland Park, Kansas, specialized in early phase and multi-site clinical trials across therapeutic areas including neuroscience, infectious diseases, and cardiometabolic disorders, has announced that …

Continue ›››